NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 242.86 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.08 (1.55%)

This chart shows the closing price for AVEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AVEO Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVEO

Analyst Price Target is $18.00
▲ +242.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for AVEO Pharmaceuticals in the last 3 months. The average price target is $18.00, with a high forecast of $26.00 and a low forecast of $9.00. The average price target represents a 242.86% upside from the last price of $5.25.

This chart shows the closing price for AVEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in AVEO Pharmaceuticals. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/12/2021HC WainwrightLower Price TargetBuy$27.00 ➝ $19.00High
3/17/2021HC WainwrightReiterated RatingBuyLow
3/11/2021SVB LeerinkBoost Price TargetOutperform$10.00 ➝ $18.00High
3/9/2021SVB LeerinkReiterated RatingBuyLow
1/19/2021SVB LeerinkBoost Price TargetOutperform$7.00 ➝ $10.00Medium
11/12/2020HC WainwrightReiterated RatingBuyMedium
11/9/2020Stifel NicolausInitiated CoverageBuy$9.00High
9/2/2020Piper SandlerReiterated RatingOverweight$26.00Low
8/13/2020SVB LeerinkInitiated CoverageOutperform$7.00High
6/1/2020HC WainwrightReiterated RatingBuy$10.00 ➝ $12.00High
5/29/2020Piper SandlerBoost Price TargetOverweight$18.50 ➝ $26.00High
5/29/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$15.00 ➝ $24.00High
5/1/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $10.00High
4/1/2020Piper SandlerLower Price TargetOverweight$20.00 ➝ $18.50High
4/1/2020HC WainwrightReiterated RatingBuy$4.00 ➝ $6.00High
3/18/2020HC WainwrightBoost Price TargetBuy$1.75 ➝ $4.00High
11/4/2019Piper Jaffray CompaniesLower Price TargetOverweight$40.00 ➝ $20.00High
10/1/2019HC WainwrightReiterated RatingBuy$17.50Medium
9/11/2019HC WainwrightUpgradeNeutral ➝ Buy$10.00 ➝ $17.50Medium
9/10/2019Piper Jaffray CompaniesBoost Price TargetOverweight$30.00 ➝ $40.00High
3/28/2019National SecuritiesInitiated CoverageSellHigh
3/18/2019HC WainwrightReiterated RatingHold$10.00High
2/4/2019B. RileyReiterated RatingBuy ➝ Neutral$50.00 ➝ $10.00High
2/1/2019HC WainwrightDowngradeBuy ➝ Neutral$10.00High
1/31/2019Piper Jaffray CompaniesReiterated RatingOverweight$50.00 ➝ $30.00High
1/14/2019HC WainwrightReiterated RatingBuy$90.00High
1/8/2019B. RileyInitiated CoverageBuy$50.00Low
1/3/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$30.00High
12/20/2018(FBRC)Set Price TargetBuy$30.00Medium
12/13/2018HC WainwrightSet Price TargetBuy$90.00High
11/6/2018National SecuritiesDowngradeBuy ➝ NeutralHigh
11/6/2018HC WainwrightSet Price TargetBuy ➝ Buy$90.00High
10/23/2018HC WainwrightSet Price TargetBuy$70.00High
8/16/2018HC WainwrightInitiated CoverageBuy$65.00Medium
1/16/2018B. RileyReiterated RatingBuy$50.00High
11/13/2017B. RileyInitiated CoverageBuy ➝ Buy$50.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuyN/A
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$38.00 ➝ $45.00High
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00Low
7/13/2017(FBRC)Reiterated RatingOutperform$30.00High
6/30/2017(FBRC)Reiterated RatingBuy$30.00Low
6/24/2017Piper Jaffray CompaniesSet Price TargetBuy$20.00High
6/23/2017Piper Jaffray CompaniesReiterated RatingPositiveHigh
5/22/2017(FBRC)Reiterated RatingOutperform$30.00High
4/17/2017(FBRC)Reiterated RatingOutperform$30.00High
4/8/2017(FBRC)Reiterated RatingBuyLow
3/25/2017(FBRC)Reiterated RatingOutperform$30.00Medium
2/27/2017(FBRC)Reiterated RatingOutperform$30.00N/A
9/13/2016(FBRC)Reiterated RatingBuyN/A
8/8/2016(FBRC)Reiterated RatingBuyN/A
(Data available from 8/2/2016 forward)
AVEO Pharmaceuticals logo
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $5.25
Low: $5.10
High: $5.28

50 Day Range

MA: $6.35
Low: $5.12
High: $7.34

52 Week Range

Now: $5.25
Low: $4.25
High: $18.24


214,449 shs

Average Volume

1,408,540 shs

Market Capitalization

$180.40 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of AVEO Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on AVEO Pharmaceuticals in the last twelve months: HC Wainwright, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for AVEO.

What is the current price target for AVEO Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for AVEO Pharmaceuticals in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 242.9%. Piper Sandler has the highest price target set, predicting AVEO will reach $26.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $9.00 for AVEO Pharmaceuticals in the next year.
View the latest price targets for AVEO.

What is the current consensus analyst rating for AVEO Pharmaceuticals?

AVEO Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVEO will outperform the market and that investors should add to their positions of AVEO Pharmaceuticals.
View the latest ratings for AVEO.

What other companies compete with AVEO Pharmaceuticals?

How do I contact AVEO Pharmaceuticals' investor relations team?

AVEO Pharmaceuticals' physical mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company's listed phone number is 857-400-0101 and its investor relations email address is [email protected] The official website for AVEO Pharmaceuticals is